Evidence map›Paper›PMID 23514728›Full record

Trial reportDiabetes care2013

Large pre- and postexercise rapid-acting insulin reductions preserve glycemia and prevent early- but not late-onset hypoglycemia in patients with type 1 diabetes.

Matthew D Campbell, Mark Walker, Michael I Trenell, Djordje G Jakovljevic, Emma J Stevenson, Richard M Bracken, Stephen C Bain, Daniel J West

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02660242 (The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes), which is not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02660242 phase2completednot on this mapstarted 2016, after this paper: background citation

The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

TypeinterventionalSponsorJaeb Center for Health ResearchRan2016 to 2017Enrolled16ConditionsDiabetes Mellitus, Type 1ArmsG-Pen Mini™ (glucagon injection), Glucose Tabs, Basal Insulin Reduction
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 78 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Association of HbA1c with VOMetabolites · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Matthew D CampbellCorresponding author: Daniel J. West, d.j.west@northumbria.ac.uk.
Mark Walker
Michael I Trenell
Djordje G Jakovljevic
Emma J Stevenson
Richard M Bracken
Stephen C Bain
Daniel J West
Northumbria University · GBNewcastle University · GBSwansea University · GBNewcastle Hospitals - Campus for Ageing and Vitality · GB

Funding

Department of Health SRF-2011-04-017Medical Research Council MC_G0802536
6 · The paper itself

Abstract

objectiveTo examine the acute and 24-h glycemic responses to reductions in postexercise rapid-acting insulin dose in type 1 diabetic patients. RESEARCH DESIGN AND

methodsAfter preliminary testing, 11 male patients (24 ± 2 years, HbA1c 7.7 ± 0.3%; 61 ± 3.4 mmol/mol) attended the laboratory on three mornings. Patients consumed a standardized breakfast (1 g carbohydrate · kg(-1) BM; 380 ± 10 kcal) and self-administered a 25% rapid-acting insulin dose 60 min prior to performing 45 min of treadmill running at 72.5 ± 0.9% VO2peak. At 60 min postexercise, patients ingested a meal (1 g carbohydrate · kg(-1) BM; 660 ± 21 kcal) and administered a Full, 75%, or 50% rapid-acting insulin dose. Blood glucose concentrations were measured for 3 h postmeal. Interstitial glucose was recorded for 20 h after leaving the laboratory using a continuous glucose monitoring system.

resultsAll glycemic responses were similar across conditions up to 60 min postexercise. After the postexercise meal, blood glucose was preserved under 50%, but declined under Full and 75%. Thence at 3 h, blood glucose was highest under 50% (50% [10.4 ± 1.2] vs. Full [6.2 ± 0.7] and 75% [7.6 ± 1.2 mmol · L(-1)], P = 0.029); throughout this period, all patients were protected against hypoglycemia under 50% (blood glucose ≤ 3.9; Full, n = 5; 75%, n = 2; 50%, n = 0). Fifty percent continued to protect patients against hypoglycemia for a further 4 h under free-living conditions. However, late-evening and nocturnal glycemia were similar; as a consequence, late-onset hypoglycemia was experienced under all conditions.

conclusionsA 25% pre-exercise and 50% postexercise rapid-acting insulin dose preserves glycemia and protects patients against early-onset hypoglycemia (≤ 8 h). However, this strategy does not protect against late-onset postexercise hypoglycemia.

Indexed as

AdultBlood GlucoseCross-Over StudiesDiabetes Mellitus, Type 1ExerciseHumansHypoglycemiaHypoglycemic AgentsInsulinInsulin, Short-ActingMaleSleepBlood GlucoseHypoglycemic AgentsInsulinInsulin, Short-Acting

Identifiers

PMID23514728
PMCPMC3714511
OpenAlexW2142003793

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.